Study focuses in on potential cause of antipsychotic-induced diabetes.
First-generation antipsychotic drugs, efficacious in reducing the "positive" syndrome of schizophrenia, carried serious motor side effects, such as immobility and Parkinsonism. While second-generation antipsychotics have reduced the incidence of such effects, they are not without risk. It has come to light that both first- and second-generation antipsychotics are associated with weight gain and type 2 diabetes. This short review addresses this issue, as well as covers recent studies to find which neurotransmitter receptors may be involved in the induction of these metabolic disturbances.
O'Neill
Michael F
MF
Eolas Biosciences Ltd., London, UK. mfon@eolasbio.co.uk
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D043587:Receptor, Muscarinic M3 / Q000378:metabolism*; D011969:Receptors, Histamine H1 / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D015430:Weight Gain
D014150:Antipsychotic Agents; D043587:Receptor, Muscarinic M3; D011969:Receptors, Histamine H1; D005947:Glucose